AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...
Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.
In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.
AstraZeneca PLC AZN shares rallied 1.33% to £117.20 Thursday, on what proved to be an all-around great trading session for ...
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...
AstraZeneca’s FluMist approval for self-administration could increase flu vaccine uptake: GlobalData
According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...
AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp. (TM), AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback